0000914190-19-000488.txt : 20191217 0000914190-19-000488.hdr.sgml : 20191217 20191217163244 ACCESSION NUMBER: 0000914190-19-000488 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191212 FILED AS OF DATE: 20191217 DATE AS OF CHANGE: 20191217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Furlow Brenda S. CENTRAL INDEX KEY: 0001443851 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 191290116 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-12-12 0000842023 BIO-TECHNE Corp TECH 0001443851 Furlow Brenda S. 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413 0 1 0 0 SVP - General Counsel Common Stock 2019-11-12 5 G 0 492 0 D 2711 D Common Stock 2019-12-12 4 M 0 8000 94.35 A 10711 D Common Stock 2019-12-12 4 S 0 426 214.3196 D 10285 D Common Stock 2019-12-12 4 S 0 3227 215.1651 D 7058 D Common Stock 2019-12-12 4 S 0 4147 216.0077 D 2911 D Common Stock 2019-12-12 4 S 0 200 216.75 D 2711 D Stock Options (Right to Buy) 94.35 2019-12-12 4 M 0 8000 0 D 2021-08-12 Common Stock 8000 1600 D Stock Options (Right to Buy) 108.49 2022-08-07 Common Stock 10000 10000 D Stock Options (Right to Buy) 108.49 2022-08-07 Common Stock 5995 5995 D Stock Options (Right to Buy) 106.59 2023-08-18 Common Stock 10857 10857 D Stock Options (Right to Buy) 106.59 2023-08-18 Common Stock 14476 14476 D Restricted Stock Units Common Stock 1724 1724 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 9503 9503 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 12670 12670 D Restricted Stock Units Common Stock 1374 1374 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 7339 7339 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 9786 9786 D Restricted Stock Units Common Stock 1969 1969 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 9968 9968 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 13290 13290 D Represents a transfer of shares to a charitable donor advised fund. The reporting person retained no pecuniary interest in the transferred shares. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.67 to $214.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.69 to $215.68 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.69 to $216.53 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.71 to $216.79 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Fully exercisable. Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022. Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021. Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023. Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). /s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed. 2019-12-17